The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a phase 1 study of vosilasarm (EP0062), a first-in-class oral selective androgen receptor modulator (SARM) in patients with advanced or metastatic AR+/ER+/HER-2- breast cancer.
 
Hyo Han
Consulting or Advisory Role - Arvinas; Pfizer
Research Funding - Arvinas (Inst); Celcuity (Inst); Department of Defense (Inst); Eisai; Ellipses Pharma; Mersana; Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Pionyr (Inst); QuantumLeap Health (Inst); Senhwa Biosciences (Inst); Zymeworks (Inst)
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Actuate Therapeutics; Agenus; Amgen; AstraZeneca; Atreca; BAKX Therapeutics; Boehringer Ingelheim; Compass Therapeutics; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; ImCheck therapeutics; IQvia; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Mersana; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Quanta Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Scenic Biotech; Schrodinger; Seagen; Sotio; ST Cube; Stemline Therapeutics; Takeda; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Erika Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); Arvinas (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Johnson and Johnson (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Noelia Martinez-Jañez
Consulting or Advisory Role - Pfizer
Research Funding - Lilly; Novartis; Pfizer
 
Valentina Boni
Employment - Next Oncology; Next Oncology; Quironsalud
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Rodrigo Sanchez-Bayona
Honoraria - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Lilly; Novartis; Roche
Speakers' Bureau - AstraZeneca; Novartis
Expert Testimony - AstraZeneca; Lilly; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
(OPTIONAL) Uncompensated Relationships - ESMO
 
Carlo Palmieri
Honoraria - AstraZeneca; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Digistain; Exact Sciences; Gilead Sciences; Lilly; Novartis; Pfizer; Seagen; Stemline Therapeutics
Research Funding - Daiichi-Sankyo (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Anne Armstrong
Stock and Other Ownership Interests - AstraZeneca (I)
Consulting or Advisory Role - Gilead Sciences; MSD; Novartis/Ipsen; Roche
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; MSD Oncology; Novartis; Roche
Other Relationship - Gilead Sciences (Inst)
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Geoff Fisher
Employment - Ellipses Pharma
 
Sue Brook
Employment - Ellipses Pharma
 
Hendrik-Tobias Arkenau
Employment - Ellipses Pharma; Hospital Corporation of America; SArah CAnnon Research Institute UK; SArah CAnnon Research Institute UK
Honoraria - BeiGene; Guardant Health; SERVIER
Consulting or Advisory Role - Engitix; iOnctura
Research Funding - Sarah Cannon Research Institute
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis; Roche